C’ (formerly Invossa) failed to demonstrate therapeutic efficacy in its first U.S. Phase 3 clinical trial. Jeon Seung-ho, ...
Kolon TissueGene’s cell and gene therapy for osteoarthritis, TG-C, failed to demonstrate efficacy in pain reduction and joint function improvement in ...